Kenvue Inc. (KVUE) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the fiscal quarter ended September 29, 2024. Kenvue Inc. is a global consumer health company operating three segments: Self Care, Skin Health and Beauty, and Essential Health. The company is fully independent following its separation from Johnson & Johnson (J&J), with J&J no longer holding any equity as of May 2024.
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Net Sales ($ millions) | $3,899 | $3,915 | $11,793 | $11,778 |
| Operating Income ($ millions) | $654 | $710 | $1,358 | $2,052 |
| Net Income ($ millions) | $383 | $438 | $737 | $1,337 |
| Diluted EPS ($) | $0.20 | $0.23 | $0.38 | $0.73 |
| Gross Margin (%) | 58.5% | 57.5% | 58.4% | 56.0% |
| Operating Cash Flow (YTD, $ millions) | $976 | $2,218 | - | - |
| Total Debt ($ millions) | $8,701 | - | - | - |
| Cash and Equivalents ($ millions) | $1,057 | - | - | - |
Material Changes vs. Prior Period
- Revenue: Q3 Net sales decreased 0.4% year-over-year, driven by a 1.6% volume decline partially offset by 2.5% value realization (price/mix). YTD sales were flat (+0.1%).
- Profitability: Operating income declined 7.9% in Q3 and 33.8% YTD. The YTD decline is primarily due to a $578 million impairment charge recognized in the first half of the year, largely related to the Dr.Ci:Labo brand ($488 million) and the interim corporate headquarters ($68 million).
- Restructuring: The company incurred $31 million in restructuring expenses in Q3 and $120 million YTD as part of the "2024 Multi-Year Restructuring Initiative" aimed at optimizing cost structure.
- Segment Performance: Essential Health showed strong growth (+1.6% Q3, +3.4% YTD). Skin Health and Beauty declined (-4.2% Q3, -4.4% YTD) due to competitive pressures and volume decreases in the U.S. and China.
Guidance, Outlook, and Risks
- Restructuring Outlook: The 2024 Multi-Year Restructuring Initiative is expected to result in total pre-tax charges of approximately $550 million. Management anticipates lower spend in 2024 than originally planned due to timing shifts and lower employee-related costs.
- Capital Allocation: The company paid $1.159 billion in dividends YTD and repurchased $114 million of treasury stock. A new dividend of $0.205 per share was declared in October 2024.
- Legal Contingencies: Significant litigation risks remain regarding talc products (outside U.S./Canada), acetaminophen (autism/ADHD claims), and phenylephrine (PE) efficacy. J&J retains liability for U.S./Canada talc claims.
- Market Risks: Exposure to foreign currency fluctuations, inflationary pressures on raw materials, and geopolitical instability (Russia-Ukraine, Middle East).
Investor Verification Checklist
- Impairment Details: Verify the long-term strategic impact of the $488 million Dr.Ci:Labo impairment on the Skin Health segment's future cash flows.
- Volume Trends: Assess the sustainability of volume declines in the Skin Health and Beauty segment amidst competitive pressures.
- Restructuring Execution: Monitor the realization of cost savings from the $550 million restructuring initiative against the timeline.
- Legal Exposure: Review updates on the phenylephrine (PE) litigation and talc liabilities outside the U.S. and Canada.
- Debt Servicing: Confirm the ability to service $8.7 billion in total debt given the current interest rate environment and operating cash flow trends.